[go: up one dir, main page]

NO991494D0 - <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer - Google Patents

<beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer

Info

Publication number
NO991494D0
NO991494D0 NO991494A NO991494A NO991494D0 NO 991494 D0 NO991494 D0 NO 991494D0 NO 991494 A NO991494 A NO 991494A NO 991494 A NO991494 A NO 991494A NO 991494 D0 NO991494 D0 NO 991494D0
Authority
NO
Norway
Prior art keywords
matrix metalloproteinase
beta
metalloproteinase inhibitors
sulfonylhydroxamic
acids
Prior art date
Application number
NO991494A
Other languages
English (en)
Other versions
NO991494L (no
NO312893B1 (no
Inventor
Martha A Warpehoski
Donald E Harper
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO991494D0 publication Critical patent/NO991494D0/no
Publication of NO991494L publication Critical patent/NO991494L/no
Publication of NO312893B1 publication Critical patent/NO312893B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19991494A 1996-09-27 1999-03-26 <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer, og farmasöytisk preparatinneholdende disse NO312893B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (3)

Publication Number Publication Date
NO991494D0 true NO991494D0 (no) 1999-03-26
NO991494L NO991494L (no) 1999-05-26
NO312893B1 NO312893B1 (no) 2002-07-15

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991494A NO312893B1 (no) 1996-09-27 1999-03-26 <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer, og farmasöytisk preparatinneholdende disse

Country Status (21)

Country Link
US (2) US5847153A (no)
EP (1) EP0929519B1 (no)
JP (1) JP2001516338A (no)
KR (1) KR20000048639A (no)
CN (1) CN1158254C (no)
AT (1) ATE289590T1 (no)
AU (1) AU726799B2 (no)
BR (1) BR9712134A (no)
CA (1) CA2266368A1 (no)
CZ (1) CZ92399A3 (no)
DE (1) DE69732571T2 (no)
EA (1) EA001460B1 (no)
ES (1) ES2236829T3 (no)
HU (1) HUP0000145A3 (no)
ID (1) ID21897A (no)
IL (1) IL128900A0 (no)
NO (1) NO312893B1 (no)
NZ (1) NZ334729A (no)
PL (1) PL332509A1 (no)
UA (1) UA48262C2 (no)
WO (1) WO1998013340A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
JP2000517297A (ja) * 1996-08-07 2000-12-26 ダーウィン・ディスカバリー・リミテッド Ｍｍｐとｔｎｆの抑制活性を有するヒドロキサム酸誘導体およびカルボン酸誘導体
ES2236829T3 (es) * 1996-09-27 2005-07-16 PHARMACIA &amp; UPJOHN COMPANY LLC Acidos beta-sulfonil hidroxamicos como inhibidores de las metaloproteinas de la matriz.
JP4456183B2 (ja) 1997-01-22 2010-04-28 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド 置換β−チオカルボン酸類
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
CA2283145A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CN1168709C (zh) 1997-11-21 2004-09-29 厄普约翰药物公司 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物
CN100402496C (zh) * 1998-01-30 2008-07-16 达尔文发现有限公司 用作基质金属蛋白酶抑制剂的化合物
DK1357109T3 (da) 1998-06-18 2008-09-08 Hoffmann La Roche Fremgangsmåde til arylalkylsulfid
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) * 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2007070760A2 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
MX2009002888A (es) 2006-09-25 2009-03-31 Boehringer Ingelheim Int Compuestos que modulan el receptor cb2.
CA2704684A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2730037A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
PE20110397A1 (es) 2008-09-25 2011-07-01 Boehringer Ingelheim Int Compuestos que modulan selectivamente el receptor cb2
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2480544A1 (en) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
ES2236829T3 (es) 1996-09-27 2005-07-16 PHARMACIA &amp; UPJOHN COMPANY LLC Acidos beta-sulfonil hidroxamicos como inhibidores de las metaloproteinas de la matriz.
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
DE69732571D1 (de) 2005-03-31
HUP0000145A2 (en) 2000-07-28
PL332509A1 (en) 1999-09-13
EP0929519B1 (en) 2005-02-23
AU4645997A (en) 1998-04-17
US6235928B1 (en) 2001-05-22
BR9712134A (pt) 1999-08-31
CA2266368A1 (en) 1998-04-02
ATE289590T1 (de) 2005-03-15
WO1998013340A1 (en) 1998-04-02
EA001460B1 (ru) 2001-04-23
KR20000048639A (ko) 2000-07-25
CN1230177A (zh) 1999-09-29
CN1158254C (zh) 2004-07-21
HUP0000145A3 (en) 2001-12-28
NZ334729A (en) 2001-01-26
EP0929519A1 (en) 1999-07-21
EA199900332A1 (ru) 1999-12-29
DE69732571T2 (de) 2006-01-12
HK1022468A1 (en) 2000-08-11
JP2001516338A (ja) 2001-09-25
US5847153A (en) 1998-12-08
NO991494L (no) 1999-05-26
NO312893B1 (no) 2002-07-15
ID21897A (id) 1999-08-05
UA48262C2 (uk) 2002-08-15
CZ92399A3 (cs) 1999-07-14
IL128900A0 (en) 2000-01-31
AU726799B2 (en) 2000-11-23
ES2236829T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
NO991494L (no) &lt;beta&gt;-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
DK1140918T3 (da) Thrombininhibitorer
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
NO965568D0 (no) Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinaseinhibitorer
ATE297203T1 (de) Antithrombotische mitteln
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
DE69831868D1 (en) Antithrombosemittel
CA2367017A1 (en) Inhibitors of impdh enzyme
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR0010555A (pt) Inibidores de neuraminidases
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
NO20003018L (no) Triazinangiogenese-inhibitorer
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DK0804418T3 (da) Platelataggregationshæmmere
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
ATE282608T1 (de) Chinoxalindionen
ECSP982805A (es) Compuestos de tiourea y benzamida, composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
TH29600B (th) &#34;อะเซเพนและโฮโมโลกัสของมัน การเตรียมและการใช้สารเหล่านี้เป็นเวชภัณฑ์&#34;